Provided by Tiger Trade Technology Pte. Ltd.

Belite Bio, Inc.

141.32
-8.9200-5.94%
Post-market: 141.320.00000.00%18:40 EST
Volume:169.96K
Turnover:24.59M
Market Cap:5.30B
PE:-73.26
High:151.16
Open:150.25
Low:140.99
Close:150.24
52wk High:161.32
52wk Low:49.00
Shares:37.51M
Float Shares:19.96M
Volume Ratio:0.59
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9290
EPS(LYR):-1.1836
ROE:-32.30%
ROA:-21.22%
PB:19.34
PE(LYR):-119.40

Loading ...

Belite Bio Announces Positive Phase 3 Results for Tinlarebant in Stargardt Disease

Reuters
·
Dec 01

Belite Bio Inc - to File Nda With FDA in 1H 2026

THOMSON REUTERS
·
Dec 01

Belite Bio Inc: Tinlarebant Was Well Tolerated Throughout Trial

THOMSON REUTERS
·
Dec 01

New Hope for People Living With a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results From the Pivotal Global, Phase 3 Dragon Trial of Tinlarebant in Adolescents With Stargardt Disease

THOMSON REUTERS
·
Dec 01

Belite Bio Inc: Tinlarebant Met Primary Efficacy Endpoint in a Global Phase 3 Trial

THOMSON REUTERS
·
Dec 01

Belite Bio rises 16.3%

TIPRANKS
·
Nov 24

Belite Bio Coverage Assumed by Cantor Fitzgerald at Overweight

Dow Jones
·
Nov 24

Belite Bio Assigns Columbia University License to Swiss Subsidiary

Reuters
·
Nov 24

U.S. RESEARCH ROUNDUP-Alignment Healthcare, BJ's Wholesale Club Holdings, Hyatt Hotels

Reuters
·
Nov 24

Belite Bio Inc : Mizuho Initiates Coverage With Neutral Rating; Target Price $105

THOMSON REUTERS
·
Nov 20

Belite Bio Says UK's MHRA Agrees To Conditional Marketing Authorization For Treatment Of Stargardt Disease With Tinlarebant

Reuters
·
Nov 20

Stock Track | Belite Bio Soars 5.43% as Maxim Group Boosts Price Target to $140

Stock Track
·
Nov 12

U.S. RESEARCH ROUNDUP-Floor & Decor Holdings, Composecure, Outfront Media

Reuters
·
Nov 12

Belite Bio Inc : Maxim Group Raises Target Price to $140 From $110

THOMSON REUTERS
·
Nov 12

Belite Bio on Track for Largest Percent Decrease Since December 2024 -- Data Talk

Dow Jones
·
Nov 12

Benchmark Co. Sticks to Their Buy Rating for Belite Bio, Inc. ADR (BLTE)

TIPRANKS
·
Nov 11

Stock Track | Belite Bio Soars 5.16% on Positive Corporate Update and Clinical Trial Progress Despite Wider Q3 Loss

Stock Track
·
Nov 11

Stock Track | Belite Bio Soars 5.16% on Positive Drug Development Progress and Strong Financial Position

Stock Track
·
Nov 11

Earnings Flash (BLTE) Belite Bio Posts Q3 Net Loss $0.65 a Share, vs. FactSet Est. of $0.45 Loss

MT Newswires Live
·
Nov 10

Belite Bio Q3 net loss widens on higher R&D expenses

Reuters
·
Nov 10